|Over a month ago|
Context Therapeutics 1.5M share IPO price range $12.00-$14.00 » 12:0907/1307/13/21
ThinkEquity is acting as…
ThinkEquity is acting as sole book running manager for the offering.
|Over a quarter ago|
Centrexion raises $40.5M, adds Lilly, Exome asset Management as investors » 08:1110/2910/29/20
Centrexion Therapeutics (CNTX) announced that it has raised $40.5 million of cash via: Convertible security investments from Lilly (LLY) and Exome Asset Management - each a new investor in Centrexion; Collaboration-related investment from Lilly which signifies continued confidence in our joint compound; and Expanded lending from the existing debt facility with Solar Capital Partners, LLC. Inclusive of this $40.5 million raise, Centrexion has in excess of $75 million of cash to deploy for the continued in-licensing of drug candidates and development of its portfolio of four clinical-stage drug candidates including: 4975 in Phase 3 for knee osteoarthritis pain; 6970 in Phase 2a for osteoarthritis pain; 6016 in Phase 1b/2a for diabetic neuropathy; 0290 in Phase 2a for neuropathic, musculoskeletal and inflammatory pain. In addition to the drug candidates listed above, Centrexion expects to close within the next few months on the acquisition of another mid-development stage drug candidate addressing pain.